Literature DB >> 18538383

Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3.

Kevin O Kisich1, Charles W Carspecken, Stephanie Fiéve, Mark Boguniewicz, Donald Y M Leung.   

Abstract

BACKGROUND: Individuals with atopic dermatitis (AD) have frequent colonization and infection with Staphylococcus aureus. Rapid elimination of S. aureus depends on constitutive synthesis and mobilization of human beta-defensin-3 (HBD-3).
OBJECTIVE: To determine whether keratinocytes in AD, compared with normal, skin are less able to kill S. aureus rapidly, and to assess the potential role that abnormally low mobilization of HBD-3 onto S. aureus has in this process.
METHODS: Skin samples from 10 normal individuals and 10 patients with AD were compared for synthesis and mobilization of HBD-3 onto surface-associated S. aureus. Furthermore, keratinocytes from 10 individuals were studied for the effects of T(H)2 cytokines on the ability of the cells to synthesize and mobilize HBD-3, and to kill S. aureus.
RESULTS: Keratinocytes in skin biopsies from subjects with AD were defective in killing S. aureus relative to normal individuals (P < .001). The constitutive levels of HBD-3 in the epidermal keratinocytes were similar between normal individuals and those with AD. However, the cells of patients with AD were unable to mobilize HBD-3 efficiently to kill S. aureus. Physiologic Ca(++) was essential for development of normal HBD-3 levels by cultured human keratinocytes. Mobilization of HBD-3 and the ability to kill S. aureus were significantly (P < .05) inhibited by IL-4 and IL-13. Antagonism of IL-4/10/13 with antibodies significantly (P < .01) improved mobilization of HBD-3 onto the surface of S. aureus by skin from patients with AD.
CONCLUSION: Patients with AD have problems with S. aureus skin infection. This is a result of increased levels of T(H)2 cytokines, which inhibit keratinocyte mobilization of HBD-3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538383     DOI: 10.1016/j.jaci.2008.04.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  44 in total

Review 1.  Epithelial antimicrobial defence of the skin and intestine.

Authors:  Richard L Gallo; Lora V Hooper
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

2.  Atopic conditions other than asthma and risk of the 2009 novel H1N1 infection in children: a case-control study.

Authors:  Carlos F Santillan Salas; Sonia Mehra; Maria R Pardo Crespo; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2013 Sep-Oct       Impact factor: 2.587

3.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

4.  Skin barrier defects in atopic dermatitis.

Authors:  Rachana Agrawal; Judith A Woodfolk
Journal:  Curr Allergy Asthma Rep       Date:  2014-05       Impact factor: 4.806

5.  Activity, expression and genetic variation of canine β-defensin 103: a multifunctional antimicrobial peptide in the skin of domestic dogs.

Authors:  Brian C Leonard; Stanley L Marks; Catherine A Outerbridge; Verena K Affolter; Anchasa Kananurak; Amy Young; Peter F Moore; Danika L Bannasch; Charles L Bevins
Journal:  J Innate Immun       Date:  2012-01-19       Impact factor: 7.349

Review 6.  Chronic rhinosinusitis phenotypes.

Authors:  John W Steinke; Larry Borish
Journal:  Ann Allergy Asthma Immunol       Date:  2016-09       Impact factor: 6.347

Review 7.  The roles of antimicrobial peptides in innate host defense.

Authors:  Gill Diamond; Nicholas Beckloff; Aaron Weinberg; Kevin O Kisich
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 8.  Advances in basic and clinical immunology in 2008.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

9.  beta2-agonists promote host defense against bacterial infection in primary human bronchial epithelial cells.

Authors:  Claire A Gross; Russell P Bowler; Rebecca M Green; Andrew R Weinberger; Christina Schnell; Hong Wei Chu
Journal:  BMC Pulm Med       Date:  2010-05-14       Impact factor: 3.317

10.  Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute.

Authors:  Michael J Schurr; Kevin N Foster; John M Centanni; Allen R Comer; April Wicks; Angela L Gibson; Christina L Thomas-Virnig; Sandy J Schlosser; Lee D Faucher; Mary A Lokuta; B Lynn Allen-Hoffmann
Journal:  J Trauma       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.